New drugs for pulmonary fibrosis – are there any blockbusters around the corner?
Date Recorded: 30th March 2021
This webinar will catch health professionals up on the latest in drug development and clinical trials in pulmonary fibrosis.
It is so heartening to be able to speak optimistically about the future when we see our patients with IPF and other interstitial lung disease in the clinic. Not only do we have two approved drugs, but there are multiple potential breakthrough treatments in clinical development right now, many of them in late phase clinical trials.
Presenters and topics:
- Prof Glen Westall – “Current thoughts on pathogenesis of IPF and potential pathways of therapeutic target”
- Prof Dan Chambers – “Current and upcoming clinical trials”
Prof Glen Westall is a Consultant Chest Physician, and Head of the Paediatric Lung Transplant Program at the Alfred Hospital, Melbourne. He trained at King’s College London, and completed his respiratory training at the Alfred Hospital, Melbourne and Royal Brompton Hospital, London. Glen is a lead Consultant in Melbourne’s largest dedicated Lung Fibrosis service that operates within the Department of Respiratory Medicine at the Alfred Hospital.
Prof Dan Chambers is a thoracic and transplant physician with special interests in immunology and interstitial lung disease. After graduating from The University of Queensland (1993, University Medal) he trained in thoracic medicine and transplantation and completed an MD. Dan is now Director of the World Lung and Heart-lung Transplant Registry – the first Australian to hold that position.
In collaboration with:
The Centre for Research Excellence in Pulmonary Fibrosis & Pulmonary Fibrosis Australasian Clinical Trials (PACT) Network
To register your interest in the on-demand recording, please register below. You will then be sent an e-mail, allowing you to obtain the recording links through Vimeo.
|Category||Fee (excl. GST)|
Please contact the TSANZ Office on +61 2 9222 6200 or e-mail firstname.lastname@example.org